Stephen Elledge (Emmanuel Ording, Harvard)

Stephen Elledge's Har­vard lab again proves fruit­ful with the launch of high-through­put an­ti­body start­up

Af­ter work­ing with es­teemed Har­vard pro­fes­sor Stephen Elledge to launch TCR-fo­cused TScan Ther­a­peu­tics three years ago, the Long­wood Fund ap­proached the sci­en­tist last spring about spin­ning out more of his work.

To­geth­er, they launched a Cam­bridge, MA-based start­up in De­cem­ber called Im­muneID, which us­es Elledge’s plat­form to iden­ti­fy and tar­get the an­ti­body in­ter­ac­tions that dri­ve im­mune dis­eases, like se­vere al­ler­gies. And on Wednes­day morn­ing, the com­pa­ny un­veiled a $50 mil­lion Se­ries A round, bring­ing its to­tal raise to over $70 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.